B+
Bull case
20%
Probability
Target price
$6.00
Analysis reference price unavailable
Analysis 2026-01-09 · RankAlpha Sentiment AI
ORMP
OramedFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment AIMost likely
B
Base case
55%
Probability
Target price
$3.30
Analysis reference price unavailable
Analysis 2026-01-09 · RankAlpha Sentiment AI
B-
Bear case
25%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-01-09 · RankAlpha Sentiment AI
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-01-09
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+29.6
Score
AI commentary
Market consensus price targets are narrowly clustered slightly below the anchor, producing a cautious/neutral tone among analysts [#SERP-1][#SERP-2]. Retail and forum discussion is mixed, with attention focused on upcoming corporate updates and the platform's ability to attract partners [#SERP-7]. The bull view requires binary positive clinical/BD outcomes within the next year to justify material upside; absent those outcomes, the consensus targets act as a near-term reference point.
RankAlpha Sentiment AI - 2026-01-09
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-04-09catalystNext quarterly/earnings updateHigh impact
Regular quarterly financial update / corporate progress (no firm date disclosed). Market typically re-prices on revenue guidance, cash/burn commentary and program milestones; consensus price targets cluster near $3.25–3.32 which may compress upside [#SERP-1][#SERP-2].
2026-06-30eventPartnership or licensing announcement (business development)High impact
A strategic licensing or commercial partnership would materially de-risk commercialization and could re-rate the equity; no public window disclosed, assumption: near-term BD activity may conclude in H1 2026 (using end of window) [#SERP-2].
2027-01-09catalystClinical program readouts / regulatory progressHigh impact
Potential trial readouts or regulatory interactions on oral protein delivery programs remain the principal long-term value drivers; timing is uncertain and could be >12 months [#SERP-7].
Recommendation
N/A
No formal recommendation provided.
As of 2026-01-09 • Updated nightlySource: Internal modelMethodology